Vasiliadis Angelo V, Galanis Nikiforos
2nd Orthopaedic Department of "Papageorgiou" General Hospital, Ring Road-N.Eukarpia, 56403 Thessaloniki, Greece.
Postdoctoral Researcher, School of Medicine, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.
J Stem Cells Regen Med. 2020 May 27;16(1):3-9. doi: 10.46582/jsrm.1601002. eCollection 2020.
Introduction: Knee osteoarthritis (OA) is a common pathology and is one of the leading causes of chronic disability among people aged over 65 years old. Currently, cell-based therapies involving intra-articular delivery of MSCs have emerged as a potential treatment solution. The purpose was to examine the current literature regarding the clinical application of adipose-derived mesenchymal stem cells (AD-MSCs) for the management of knee OA. The electronic database, PubMed was searched from inception to May 31, 2019. This review included studies using cell population containing AD-MSCs for the treatment of knee OA. Data on clinical outcomes measured by various instrument such as VAS, WOMAC, KSS, KOOS, SF-36 were analysed, while MRI provided reliable and quantitative data on cartilage status throughout most compartments of the knee. A total of eight studies were included. Six studies used cultured AD-MSCs, while two studies used stromal vascular fraction. There were no significant adverse events related to the procedure, while the most of studies reported improvement from baseline in at least one outcome measure. The findings were not necessarily reflected in MRI evaluations nor were improvements always maintained after 2 years follow-up. Our data suggest that the intra-articular injection of autologous AD-MSCs is a safe and effective therapeutic alternative for the treatment of severe knee OA patients and may have the potential to attenuate progression of the disease.
膝关节骨关节炎（OA）是一种常见病症，是65岁以上人群慢性残疾的主要原因之一。目前，涉及关节内注射间充质干细胞（MSCs）的细胞疗法已成为一种潜在的治疗方案。本研究旨在探讨有关脂肪源性间充质干细胞（AD-MSCs）在膝关节OA治疗中临床应用的现有文献。检索了电子数据库PubMed，检索时间从建库至2019年5月31日。本综述纳入了使用含AD-MSCs细胞群体治疗膝关节OA的研究。分析了通过各种工具（如视觉模拟评分法（VAS）、西安大略和麦克马斯特大学骨关节炎指数（WOMAC）、膝关节协会评分（KSS）、膝关节损伤和骨关节炎疗效评分（KOOS）、36项简短健康调查（SF-36））测量的临床结局数据，而磁共振成像（MRI）提供了关于膝关节大部分区域软骨状态的可靠定量数据。共纳入八项研究。六项研究使用培养的AD-MSCs，两项研究使用基质血管成分。与该治疗方法相关的严重不良事件未出现，而大多数研究报告至少一项结局指标较基线有所改善。这些结果不一定能在MRI评估中体现出来，且在2年随访后改善情况也并非总能维持。我们的数据表明，关节内注射自体AD-MSCs是治疗重度膝关节OA患者的一种安全有效的治疗选择，且可能有减缓疾病进展的潜力。
